Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The ELISPOT and FluoroSpot Assay market is experiencing substantial growth due to their expanding role in immunotherapy research. As immunotherapy continues to dominate the treatment of cancer and other therapeutic applications, such assays become a powerful tool for measuring immune responses at single-cell level. The changing market dynamics are influenced by the rising need for precise and sensitive assays to evaluate the efficacy of immunotherapies and personalize treatment depending on individual patients.
Infectious disease studies, the application of ELISPOT and FluoroSpot Assays influences market trends. Furthermore, such assays are used to characterize immune responses towards pathogens and contribute directly in the design of vaccines or diagnostic tools. In infectious disease research, reliable and high-throughput assays are the need of the hour because worldwide public figures continue to focus on infections as exemplified by cases such as COVID 19.
The ELISPOT and FluoroSpot Assay market dynamics are being impacted by the ongoing technological innovations. Automation, multiplexing capabilities and higher sensitivity have been introduced to transform the traditional approaches. The market accepts innovations in the assay that increase efficiency, reduce ambiguity and provide a comprehensive view of immune response at large all sectors.
The diagnostic applications of ELISPOT and FluoroSpot Assays in autoimmune disorders have significantly affected the market dynamics. These assays are useful for detecting and quantifying certain immunological responses associated with autoimmune diseases, thereby enabling early diagnosis and appropriate treatment. These assays have been widely adopted in clinical settings due to the rising number of autoimmune disorders.
ELISPOT and FluoroSpot Assays are playing an important role in the cancer immunology research, helping contribute to market’s development. These assays allow to investigate the immune reactions against cancer cells, evaluate effectiveness of immunotherapies and identify some possible biomarkers for personalized cures. The dynamics of the market are given impetus by constant quests for immunotherapeutic approaches in oncology.
Personalization can be considered one of the factors that are impacting and influencing the current ELISPOT and FluoroSpot Assay market.
Standardization efforts intended towards ensuring uniformity in ELISPOT and FluoroSpot Assays change market dynamics. Coordinated efforts between researchers, assay developers and regulatory agencies are committed to developing standardized protocols supported by quality control measures. This emphasis on standardization of assays increases the reliability and comparisons between different laboratories as well research institutions, thus its widespread use.
The adoption of ELISPOT and FluoroSpot Assays are contributing towards the research in autoimmune disorders which is changing the dynamics of this market. These assays help researchers understand the complex immune responses involved in autoimmune conditions, leading to the development of targeted therapies. The increasing prevalence of autoimmune disorders worldwide is driving the demand for advanced assays that can provide deeper insights into the underlying immunological mechanisms.
ELISpot and FluoroSpot Assay Market Highlights:
ELISpot and FluoroSpot Assays Market Overview
The ELISpot and FluoroSpot Assay Market size is expected to reach USD 0.8 Billion by 2032 at 13% CAGR during the forecast period 2023-2032. ELISpot and FluoroSpot Assays are sensitive methods for detecting immune cells that contain specific proteins like cytokines or antibodies. These tests are used in hospitals and research centers to detect diseases like tuberculosis and other viral infections early.
The FluoroSpot assay is a variation of the ELISpot assay that uses a combination of monoclonal antibodies and other reagents to detect infection. The rising incidence of chronic diseases, rising vaccine development to address the challenge of antibiotic resistance, and technological developments in analyzers and ELISpot and FluoroSpot assay kits are all driving market expansion. ELISpot is a critical step in the development of vaccines for a variety of diseases, including AIDS, TB, HIV, malaria, cancer, and influenza. The ELISpot test is one of the most extensively used immunoassays in vaccine evaluation studies. The FluoroSpot test combines the sensitivity of ELISpot with the capacity to evaluate multi-analyte secretion simultaneously, allowing cell population studies with varying operational parameters. The better sensitivity of the sample, statistical read-out, and convenience of use in both broad screening and individual testing contributed to this reputation. Both T-cell responses and vaccine-specific antibody-producing B cells can be assessed with this technique. As a result of the aforementioned factors, the cancer therapy market is predicted to rise rapidly over the forecast period.
ImmunoSpot introduced SpotStat Software in September 2021 for statistical analysis of ELISPOT/FluoroSpot data. The major purpose of SpotStat is to give statistically confirmed antigen-induced and negative controls differentiation. Ardigen and ImmuMap began collaborating on research in April 2021. The collaboration between ImmuMap and Ardigen will focus on finding T-cell receptors (TCRs) that are reactive to tumor-associated neoantigens. The researchers will use ELISpot assays (enzyme-linked immunosorbent assays), next-generation sequencing (NGS), MHC multimer labeling and sorting, and 10x Genomics Single Cell Immune Profiling.
In November 2023, Revvity unveiled the national release of its T-SPOT TB test for the detection of latent tuberculosis during the 46th Edition of MICROCON in Lucknow. The company asserts that its product is the sole commercially accessible IGRA (interferon gamma release assay) approved by the FDA, utilizing the ELISPOT technology. This technology encompasses the process of separating, cleansing, and quantifying peripheral blood mononuclear cells (PBMCs) from whole blood in order to provide a consistent test and yield consistent outcomes for accurate detection, particularly in difficult-to-screen populations such as those with weakened immune systems. Given that almost 40% of the Indian population carries latent TB, it is crucial to identify the infection before it develops into active disease, which is characterized by symptoms and contagiousness. The T-SPOT TB test, which utilizes the ELISPOT technology, is the sole IGRA recommended by the World Health Organization (WHO) that use a standardized sample. This helps minimize the impact of blood-related factors that could potentially impair its performance and allows for normalization in cases of cell number variation. The diagnostic recommendations of the World Health Organization (WHO) recognize the advantages of the normalization stage that is necessary before cell stimulation in the T-SPOT TB test.
In September 2023, Virax Biolabs Group Limited, a cutting-edge diagnostics firm specializing in detecting immune responses and diagnosing viral illnesses, announced the initiation of an early access program for the research-use-only of their exclusive SARS-Cov-2 ViraxImmune T-cell-based test. The early access program provides exclusive access to cutting-edge immune evaluation breakthroughs for chosen research organizations. The RUO (Research Use Only) version of Virax's T-cell-based test is specifically developed to evaluate the activation of memory T-cells that are specific to the SARS-Cov-2 virus. This is achieved by combining an ELISpot assay with a peptide pool that covers particular protein segments of the virus. The test necessitates the extraction of peripheral blood mononuclear cells from blood samples, which are subsequently placed onto the Company's pre-coated ELISpot plate.
ELISpot and FluoroSpot Assays Market Segment Insights
The ELISpot and FluoroSpot Assay Market is segmented on the basis of product, application, and end-user.
ELISpot and FluoroSpot Assays Product Insights
The market, by product is categorised into various assay kit, analyzer, ancillary products. The assay kit is sub-segmented into T Cell assay and B Cell assay.
ELISpot and FluoroSpot Assays Application Insights
On the basis of application, the market is segmented into transplant, vaccines development, clinical trials, cancer treatment.
ELISpot and FluoroSpot Assays End User Insights
On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centres, diagnostic centres, research centers, and others.
ELISpot and FluoroSpot Assays Regional Insights
On the basis of region, the ELISpot and FluoroSpot Assay Market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.
Key players:
Some of the key players in the ELISpot and FluoroSpot Assay Market are
- Oxford Immunotec (UK)
- Cellular Technologies (US)
- Mabtech (Sweden)
- Becton, Dickinson and Company (US)
- Abcam (UK)
- Bio-Techne (US)
- Autoimmun Diagnostika (Germany)
- Biotech Investissement (France)
- Lophius Biosciences (Germany)
- U-CyTech (Netherlands)
Regional Market Summary:
Sources: National Cancer Institute, Cancer research UK, the American Cancer Society, Inc, US Department of Health and Human Services National Institutes of HealthIt is estimated that North America dominated the ELISpot and FluoroSpot Assay Market owing to the increasing cardiac diseases, innovations in clinical practice, increasing research and development in pharmaceutical industries boost the market growth. According to the Centers for Disease Control and Prevention 2017 publication 83.4% of children aged 19-35 months were vaccinated with Diphtheria, Tetanus, Pertussis in the US. The increasing demand for vaccines will boost the market growth.
Europe stood second largest in the ELISpot and FluoroSpot Assay market owing to the increasing number of pharmaceutical companies, rising in the development of innovative vaccines for the treatment of various viral diseases. The growing funding from government and private agencies for drug development also support the market in this region. Asia-Pacific was estimated to be the fastest growing region for the Market in 2017. The market is expected to witness growth owing to the rising prevalence of viral infection, increasing geriatric population in this region and growing demand for ELISpot and FluoroSpot Assay in research field.
The Middle East and Africa holds the least share in the ELISpot and FluoroSpot Assay Market due to the presence of low health expenditure, lack of skilled technicians and less pharmaceutical company in this region. However, the market is expected to witness growth due to increasing research & development in the Middle East.
ELISpot and FluoroSpot Assays Market Segmentation
ELISpot and FluoroSpot Assay Product Outlook
- Assay Kit
- T Cell assay
- B Cell assay
- Analyzer
- Ancillary Products
ELISpot and FluoroSpot Assay Application Outlook
- Transplant,
- Vaccines
- Clinical Trials
- Cancer Treatment
ELISpot and FluoroSpot Assay End-User Outlook
- Hospitals and clinics
- Ambulatory surgical centers
- Diagnostic centers
- Research centers
- Others
ELISpot and FluoroSpot Assay Region Outlook
- Americas
- Europe
- Asia-Pacific
- Middle East & Africa
Recent Development
ImmunoSpot introduced SpotStat Software in September 2021 for statistical analysis of ELISPOT/FluoroSpot data. The major purpose of SpotStat is to give statistically confirmed antigen-induced and negative controls differentiation. Ardigen and ImmuMap began collaborating on research in April 2021. The collaboration between ImmuMap and Ardigen will focus on finding T-cell receptors (TCRs) that are reactive to tumor-associated neoantigens. The researchers will use ELISpot assays (enzyme-linked immunosorbent assays), next-generation sequencing (NGS), MHC multimer labeling and sorting, and 10x Genomics Single Cell Immune Profiling.
Intended Audience:
- Pharmaceutical companies
- Biotechnological institutes
- Government and private laboratories
- Research and Development (R&D) companies
- Medical research laboratories
- Market research and consulting service providers
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
